|
|
|
|
| The debate rages on. While the automation that enables continuous processing gets a lot of hype, there are plenty of dyed-in-the-wool biopharma pros who contend that process optimization and intensification yield comparable benefits, without requiring the capital-intensive process overhaul that continuous demands. Join Bioprocess Online Live for a virtual deep dive into the scalability, sustainability, and capital implications of the continuous-versus-optimized debate. Registration is free thanks to the support of Cytiva. |
|
|
|
|
By Tom Oakley, Springboard Pro | The current manufacturing strain is exacerbated by factors such as the intensity of scaling up fill-finish and specialized manufacture of drug delivery devices. How can partnering with a CDMO help? | |
|
|
| Your Most Pressing Tech Transfer Questions Answered | Article | By Edyta Bartusik-Czubek, Ph.D., Izabela Kuskowska, and Marta Bednarek, Mabion | No two tech transfers are the same. To ensure success with yours, select a CDMO that will be astute in their onboarding analysis and commit to ongoing collaboration. |
|
|
| Formulation Through Manufacturing Under One Roof | Case Study | Catalent | Partner with a CDMO that understands the unique challenges of emerging biopharma, providing expert guidance in formulation development, manufacturing, and regulatory navigation. |
|
|
|
|
|
| The Challenges Of Biopharmaceutical Quality | Q&A | Samsung Biologics | More than ever, the quality functions in biopharma manufacturing are under pressure due to regulatory and political scrutiny combined with a global market rife with complex quality standards. |
|
|
|
|
|
|
|
|
| Connect With Bioprocess Online: |
|
|
|
